Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659815 | 0.86 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL350192 | 0.86 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL21597029 | 0.86 | KDM1A (0.43) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL23885388 | 0.86 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL30053965 | 0.86 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL29365100 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTPOLBL3MBTL1KMT2A | |
| SCHEMBL275963 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTPOLBL3MBTL1KMT2A | |
| SCHEMBL21834387 | 0.79 | ALDH1A1 (0.35) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL3168767 | 0.79 | GAA (0.43) | ALDH1A1MAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL15515282 | 0.79 | CYP3A4 (0.46) | ALDH1A1MAPTPOLBL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025235686-A1 | FLUOROCAMPTOTHECIN COMPOUNDS, CONJUGATES, AND METHODS THEREOF | Aarvik Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-20240376120-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-117940432-A | Camptothecins compound, preparation method and application thereof | 上海弼领生物技术有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024073426-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1204650-A1 | SUBSTITUTED 2-ARYLBENZAZOLE COMPOUNDS AND THEIR USE AS ANTITUMOUR AGENTS | Cancer Research Ventures Limited (GB) | 2002-05-15 | — | — | EP | disclosed |
| EP-1202965-A1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001014354-A1 | SUBSTITUTED 2-ARYLBENZAZOLE COMPOUNDS AND THEIR USE AS ANTITUMOUR AGENTS | CANCER RESEARCH VENTURES LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001012603-A1 | INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| US-4935420-A | MICROBIOCIDES, ANTISEPTICS | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| US-4880806-A | BACTERICIDES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4874764-A | ANTIMICROBIALS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-10-17 | — | — | US | disclosed |
| US-4855292-A | ANTIMICROBIAL AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | ALDH1A1 716/4885MAPT 4455/4885POLB 2452/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ALDH1A1 780/4885MAPT 3072/4885POLB 4280/4885 |
| US-20240376120-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WASF2, LITAF | ALDH1A1 795/4885MAPT 4266/4885POLB 1276/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ALDH1A1 780/4885MAPT 3072/4885POLB 4280/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | ALDH1A1 1694/4885MAPT 3496/4885POLB 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.